Meet the Team
Chu Swee Yeok
Chair & Founding Partner
Chu Swee Yeok is the Chair and Founding Partner of August Global Partners (AGP), a fund management firm dedicated to investing in high-growth companies across the health and bio-ecosystem. With a career spanning decades at the forefront of strategic investment, she brings deep expertise and visionary leadership to AGP’s mission of accelerating global healthcare innovation across Asia. Prior to founding AGP, Ms. Chu served as Senior Advisor to the Chairman of Singapore’s EDBI, following her tenure as CEO, President, and Executive Director of the firm. Under her strong leadership, EDBI became a globally respected and trusted investor, building a diversified portfolio of over 200 private companies and funds across healthcare, digital innovation, financial services, and frontier engineering technologies. Ms. Chu’s entrepreneurial journey with AGP is deeply rooted in her foundational role in shaping Singapore’s biomedical sector. As the founding CEO of Bio*One Capital, she led the development of a pioneering billion-dollar fund that catalyzed innovation and commercialization in the industry—helping position Singapore as a global hub for biomedical research and enterprise. She also held senior leadership roles at EDB and A*STAR, where she played a pivotal role in crafting and executing national strategies that successfully advanced Singapore’s biomedical ambitions. Beyond her leadership at AGP, Ms. Chu continues to contribute to industry growth through her service on the boards and advisory committees of public institutions, private enterprises, and publicly listed companies—championing innovation across diverse sectors. In recognition of her contributions to public service, she was awarded the Public Service Medal in August 2025.
Basil Lui, PhD
Founding Partner
Dr Basil Lui, Founding Partner of AGP, is a seasoned investor and healthcare technology expert. As former Managing Partner at EDBI, he led investments in groundbreaking healthcare ventures, including digital healthcare platforms, precision medicine companies, AI driven healthcare solution providers, and mRNA vaccine developers. His expertise spans regenerative technologies, connected health, and emerging fields like synthetic biology and AI in healthcare. Basil's investment acumen extends to early-stage deep-tech fund-of-funds, with a focus on regional healthcare funds. His background includes roles as a McKinsey consultant, APAC President of a semiconductor EDA company, and academic positions at NUS and Cambridge University. With a PhD from Cambridge and multiple patents to his name, Basil combines deep technical knowledge with strategic investment insights, driving innovation in healthcare and emerging technologies.
Davian Sim
Managing Director, Investments
Davian is the MD, Investments of AGP. Prior to this he was the Senior Principal of Investments at EDBI where he was responsible for originating, leading and negotiating investments in areas such as Manufacturing/Advanced Manufacturing, Healthcare Services and Technology. Specifically, Davian successfully led several healthcare investment transactions in services and industrial manufacturing such as Dontia Alliance, a pan-Asian specialist focused dental services company; Meiban, an Asian based medtech manufacturer; and Esco Lifesciences, a global medical equipment and devices brand and manufacturer. He also represented EDBI as a board observer in several of its portfolio companies. Before EDBI, he was responsible for strategic investments and divestiture at Aalst-Wilmar, an associate company of Wilmar International focused on industrial chocolate and cocoa and prior to that, focused on growth and buyout transactions at BXR Group, an international private investment group specialised on large ticket investments in infrastructure, real estate and resources and; middle market investments in healthcare and education. Davian started his investment career at Credence Partners (now known as Altara Ventures), a Southeast Asian small/mid cap focused private equity fund focused on Consumer, Services, Logistics, Manufacturing and Technology. Davian’s overall deal experience ranges widely, from minority stake growth transactions and leveraged buyous, to M&As and joint ventures. Throughout his career, he was also seconded to various portfolio companies to assist with commercial negotiations, operations and strategic business development activities. Davian began his career at PrimePartners Corporate Finance, a boutique investment banking outfit advising clients on capital market transactions. He is a qualified CPA (Australia) and graduated with a Master of Applied Finance from Macquarie University, Sydney and a Bachelor of Commerce from The Australian National University, Canberra.
Warren Tan, PhD
Investments
Warren is part of the AGP Investments team. He was previously at SGInnovate, where he covered corporate engagement and venture deals under the healthcare and agrifood verticals. Earlier, he was an innovation consultant with Alcimed, where he supported corporates in innovation sourcing and technology landscaping. Warren graduated from the National University of Singapore with a PhD and BSc (1st class) in Life Sciences. In his doctoral research, he developed quantitative LC-MS panels, and screened for heart disease biomarkers in clinical cohorts. He also holds a BSc (1st class) in Applied Accounting from Oxford Brookes University and is continuing to hone his skills in finance as a CFA program participant.
Gabriel Siow
Investments
Gabriel is part of the AGP Investments team. Prior to this, he spent time with Capital Code where he worked on several transactions including capital raising, M&A, and financial due diligence in the Industrials and Food & Agriculture sectors. Before Capital Code, he was with Abacus Capital where he was involved in dozens of transactions in a wide range of industries spanning Hospitality, F&B, Agriculture, Energy, and the Services sector. Gabriel graduated from Singapore Management University with a Bachelor of Business Management (cum laude), with a major in Finance.
Chris Koh
Investments
Chris Koh is a multifaceted professional with a strong background in entrepreneurship, marketing, operations, and trading. He holds a Bachelor of Commerce with double majors in Economics and Finance from Monash University, Melbourne. Chris has essential experience in an SME, where he played a key role in marketing, operations, and business development with various industry stakeholders. He has also previously worked as an independent trader, specializing in funding arbitrage, market analysis, and risk-reward decision-making across diverse financial markets.
Operations
Jude Tan
Director, Finance & Compliance
Jude is responsible for establishing and managing all aspects of finance, compliance and operational matters in relation to AGP and its funds. He started his career in public accounting with one of the Big 4 accounting firms in Singapore, during which he spent 3 years in a secondment program to the firm’s London practice. Following that, Jude was Vice President in the Enterprise Strategy department of GIC, the sovereign wealth fund of Singapore. In that role, he supported senior management in tackling complex cross- functional issues such as sustainability (ESG), organisational design and human capital management. Prior to AGP, Jude was a pioneering team member of Greenwillow Capital Management, a licensed fund management company in Singapore. He was responsible for all middle and back office functions of the company. Jude graduated from the Nanyang Technological University with a Bachelor of Accountancy (First Class Honours), with a second major in Marketing. He is also a Chartered Accountant with the Institute of Chartered Accountants in England and Wales (ICAEW).
Jerlin Ong
Administrative Assistant
Jerlin is an adaptable administrative professional and her experience spans data review, scheduling, stakeholder engagement, event logistics, and customer service, supporting both public and private sector operations in Singapore. Jerlin excels in managing detailed records, coordinating appointments, and facilitating communications across teams. She has held leadership roles in student organizations and was twice recognized with awards for good leadership and service. Jerlin is valued for her reliability, problem-solving abilities, and commitment to operational efficiency.
Venture Partners
Shawn Tan
Venture Partner
Shawn is an investment professional with over 20 years’ experience in both private and public equity investments. He is currently the Managing Director of Axon Alpha Advisors, a family office investor with a global mandate and healthcare portfolio which includes medical devices, oncology drug development and digital health solutions. Prior to this, Shawn led private equity, technology focused investments at Novo Tellus Capital and EDBI. At Novo Tellus he led investments into companies providing advanced automation solutions for biomedical end products and at EDBI he was responsible for the Strategic Growth Programme, which invested in large local enterprises to help them compete globally. Some of his previous healthcare investment investments included Biosensors Ltd which specializes in interventional cardiology and critical care procedures, Hummingbird Bioscience, which develops breakthrough therapies for cancer treatments, Inovio Pharmaceutical Inc, which develops immunotherapies for cancer and infectious diseases, BotMD, a digital health company. He was also involved in Hyphens, a local medical product company expanding its operations in the region. Shawn other past appointments include Asia Pacific Head for Sharjah Asset Management, where he oversaw investments for UAE government funds. He was also an Investment Director at Westcomb Financial Group, a corporate finance company listed on the Singapore Stock Exchange. Earlier in his career, Shawn was part of the team that drove the commercialization and development of technology enterprises at the Agency for Science Technology and Research (A*STAR). He holds a Bachelor's with Honours Degree in Genetics and Molecular Biology from Glasgow University, UK, and a Master’s Degree in Applied Finance from Adelaide University, Australia.
Ong Jeong Shing
Venture Partner
Jeong Shing (JS) has over 15 years of global healthcare experience across corporate pharma, technology management and venture capital, including incubating and building early stage life science companies. He was Partner at EDBI, the strategic venture arm of the Economic Development Board of Singapore, leading healthcare investments in biotech, medtech, digital health and life science tools, as well as Fund of Fund investments. His investment track record and network span key geographies including USA, China, Singapore and Southeast Asia, which is complemented by his operational experience in helping portfolio companies pursue international expansion, particularly into Singapore and its surrounding Asia Pacific region. Prior to EDBI, JS oversaw investments at Venturecraft, a Singapore based boutique venture capital firm and multi-family office focusing on tech and healthcare. He successfully set up a digital health incubator supported by the Singapore government and nurtured several successful local start up companies such as Mirxes, US2.ai, Hearti Labs and Aktivo. He also established a life science accelerator in Hangzhou China, to help portfolio companies accelerate product and clinical development and gain rapid access to the Chinese market. Before starting his venture career, JS led process development and scale up at Glaxosmithkline, working across UK, US and Singapore and on multiple blockbassets in oncology and respiratory diseases. JS earned First Class Honours Degrees in Bioengineering and Chemical Engineering from the National University of Singapore, and holds an MBA with distinction from the University of Cambridge, specializing in Private Equity.